656 related articles for article (PubMed ID: 23945498)
1. Neither pre-transplant rituximab nor splenectomy affects de novo HLA antibody production after renal transplantation.
Ashimine S; Watarai Y; Yamamoto T; Hiramitsu T; Tsujita M; Nanmoku K; Goto N; Takeda A; Katayama A; Uchida K; Kobayashi T
Kidney Int; 2014 Feb; 85(2):425-30. PubMed ID: 23945498
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety of high-dose mizoribine in ABO-incompatible kidney transplantation using anti-CD20 and anti-CD25 antibody without splenectomy treatment.
Yoshimura N; Ushigome H; Matsuyama M; Nobori S; Suzuki T; Sakai K; Okajima H; Okamoto M
Transplant Proc; 2012 Jan; 44(1):140-3. PubMed ID: 22310599
[TBL] [Abstract][Full Text] [Related]
3. Results of a multicenter prospective clinical study in Japan for evaluating efficacy and safety of desensitization protocol based on rituximab in ABO-incompatible kidney transplantation.
Takahashi K; Saito K; Takahara S; Fuchinoue S; Yagisawa T; Aikawa A; Watarai Y; Yoshimura N; Tanabe K; Morozumi K; Shimazu M;
Clin Exp Nephrol; 2017 Aug; 21(4):705-713. PubMed ID: 27534951
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of 2 Doses of Rituximab on B-Cell and Antidonor Antibody and Outcomes of ABO-Incompatible Living-Donor Pediatric Kidney Transplant.
Hamasaki Y; Aikawa A; Itabashi Y; Muramatsu M; Hyoudou Y; Shinoda K; Takahashi Y; Sakurabayashi K; Mizutani T; Oguchi H; Kawamura T; Sakai K; Shishido S
Exp Clin Transplant; 2019 Jan; 17(Suppl 1):105-109. PubMed ID: 30777532
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes of ABO-incompatible kidney transplant with rituximab and double-filtration plasmapheresis.
Han S; Hwang E; Park S; Park U; Kim H; Cho W
Exp Clin Transplant; 2014 Oct; 12(5):401-4. PubMed ID: 25299367
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of blood group antibodies in ABO-incompatible living-donor kidney transplantation.
Sugiyama K; Hyodo Y; Aikawa A
Int J Urol; 2015 Oct; 22(10):931-6. PubMed ID: 26108258
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of two different preconditioning regimens for ABO-incompatible living kidney donor transplantation. A comparison of splenectomy vs. rituximab-treated non-splenectomy preconditioning regimens.
Tanabe K; Ishida H; Shimizu T; Omoto K; Shirakawa H; Tokumoto T
Contrib Nephrol; 2009; 162():61-74. PubMed ID: 19001814
[TBL] [Abstract][Full Text] [Related]
9. Three-year outcomes following 1420 ABO-incompatible living-donor kidney transplants performed after ABO antibody reduction: results from 101 centers.
Opelz G; Morath C; Süsal C; Tran TH; Zeier M; Döhler B
Transplantation; 2015 Feb; 99(2):400-4. PubMed ID: 25050471
[TBL] [Abstract][Full Text] [Related]
10. Frequent development of subclinical chronic antibody-mediated rejection within 1 year after renal transplantation with pre-transplant positive donor-specific antibodies and negative CDC crossmatches.
Yamanaga S; Watarai Y; Yamamoto T; Tsujita M; Hiramitsu T; Nanmoku K; Goto N; Takeda A; Morozumi K; Katayama A; Saji H; Uchida K; Kobayashi T
Hum Immunol; 2013 Sep; 74(9):1111-8. PubMed ID: 23792054
[TBL] [Abstract][Full Text] [Related]
11. Lower incidence of de novo donor-specific antibodies against HLA-DR in ABO-incompatible renal transplantation.
Okada M; Watarai Y; Iwasaki K; Futamura K; Yamamoto T; Hiramitsu T; Tsujita M; Goto N; Narumi S; Takeda A; Kobayashi T
Hum Immunol; 2019 Mar; 80(3):169-175. PubMed ID: 30552908
[TBL] [Abstract][Full Text] [Related]
12. The low dose of rituximab in ABO-incompatible kidney transplantation without a splenectomy: a single-center experience.
Shirakawa H; Ishida H; Shimizu T; Omoto K; Iida S; Toki D; Tanabe K
Clin Transplant; 2011; 25(6):878-84. PubMed ID: 21175849
[TBL] [Abstract][Full Text] [Related]
13. Histological and Extended Clinical Outcomes After ABO-Incompatible Renal Transplantation Without Splenectomy or Rituximab.
Chow KV; Flint SM; Shen A; Landgren A; Finlay M; Murugasu A; Masterson R; Hughes P; Cohney SJ
Transplantation; 2017 Jun; 101(6):1433-1440. PubMed ID: 27495772
[TBL] [Abstract][Full Text] [Related]
14. Single fixed low-dose rituximab as induction therapy suppresses de novo donor-specific anti-HLA antibody production in ABO compatible living kidney transplant recipients.
Tomita Y; Iwadoh K; Ogawa Y; Miki K; Kato Y; Kai K; Sannomiya A; Koyama I; Kitajima K; Nakajima I; Fuchinoue S
PLoS One; 2019; 14(10):e0224203. PubMed ID: 31644555
[TBL] [Abstract][Full Text] [Related]
15. Late-onset neutropenia and acute rejection in ABO-incompatible kidney transplant recipients receiving rituximab and mycophenolate mofetil.
Kabei K; Uchida J; Iwai T; Yamasaki T; Kuwabara N; Naganuma T; Kumada N; Nakatani T
Transpl Immunol; 2014 Aug; 31(2):92-7. PubMed ID: 24932811
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of rituximab dosage for ABO-incompatible living-donor kidney transplantation.
Nakao T; Ushigome H; Kawai K; Nakamura T; Harada S; Koshino K; Suzuki T; Ito T; Nobori S; Yoshimura N
Transplant Proc; 2015 Apr; 47(3):644-8. PubMed ID: 25891703
[TBL] [Abstract][Full Text] [Related]
17. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients.
Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R
Clin Transpl; 2014; ():215-21. PubMed ID: 26281148
[TBL] [Abstract][Full Text] [Related]
18. Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period.
Kohei N; Hirai T; Omoto K; Ishida H; Tanabe K
Am J Transplant; 2012 Feb; 12(2):469-76. PubMed ID: 22054413
[TBL] [Abstract][Full Text] [Related]
19. Pinpoint targeted immunosuppression: anti-CD20/MMF desensitization with anti-CD25 in successful ABO-incompatible kidney transplantation without splenectomy.
Saito K; Nakagawa Y; Suwa M; Kumagai N; Tanikawa T; Nishiyama T; Ueno M; Gejyo F; Nishi S; Takahashi K
Xenotransplantation; 2006 Mar; 13(2):111-7. PubMed ID: 16623803
[TBL] [Abstract][Full Text] [Related]
20. Section 15. A desensitizing protocol without local graft infusion therapy and splenectomy is a safe and effective method in ABO-incompatible adult LDLT.
Song GW; Lee SG; Hwang S; Ahn CS; Kim KH; Moon DB; Ha TY; Jung DH; Park GC; Park HW; Park YH; Kang SH; Jung BH
Transplantation; 2014 Apr; 97 Suppl 8():S59-66. PubMed ID: 24849837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
